Sangamo Therapeutics Inc. crossed an important milestone Sept. 5, becoming the first drug company to release efficacy data on a gene editing therapy in human patients. The data were early and in only four patients, but Sangamo was able to show a benefit on a key biomarker of the disease being studied.
The data also raised questions, however, because it didn't show the medicine helped patients produce a critical missing enzyme, and...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)